Industry Research Reports

Home > Reports > Medical Care > Kidney Cancer Therapeutics- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Kidney Cancer Therapeutics- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Industry: Medical Care

Published Date: 2025-01-13

Pages: 97 Pages

Report ld: 3498384

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Kidney Cancer Therapeutics Market Size(US$)

CAGR 2025-2031

3.8%

Market Size,2031

USD 585

Million

Market Snapshot

Market Size in 2025 (Value)

US$ 468 million

Market Forecast in 2031(Value)

US$ 585 million

CAGR

3.8%

Years Considered

2020-2031

Base Year

2025

Forecast Period

2025-2031

Source: Secondary research, interviews with experts, and QYResearch analysis

The global market for Kidney Cancer Therapeutics was estimated to be worth US$ 452 million in 2024 and is forecast to a readjusted size of US$ 585 million by 2031 with a CAGR of 3.8% during the forecast period 2025-2031.

Kidney cancer is cancer that begins in the kidneys. Your kidneys are two bean-shaped organs, each about the size of your fist. They"re located behind your abdominal organs, with one kidney on each side of your spine. In adults, renal cell carcinoma is the most common type of kidney cancer.

The kidney cancer therapeutics market is evolving rapidly to address the treatment needs of patients diagnosed with kidney cancer, also known as renal cell carcinoma (RCC). This market encompasses a range of therapies, including targeted therapies, immunotherapies, and combination treatments. The increasing incidence of kidney cancer, advancements in understanding its molecular basis, and the emergence of novel treatment options are driving market growth. Targeted therapies that inhibit specific pathways implicated in kidney cancer progression, along with immunotherapies that harness the immune system"s response, are gaining prominence. As research continues and personalized treatment approaches gain traction, the kidney cancer therapeutics market is expected to expand, offering new hope for improved outcomes and quality of life for patients with this challenging disease.

This report aims to provide a comprehensive presentation of the global market for Kidney Cancer Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Kidney Cancer Therapeutics by region & country, by Type, and by Application.

The Kidney Cancer Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Cancer Therapeutics.

MARKET SEGMENTATION

By Company

Merck
Novartis
Bristol-Myers Squibb
Pfizer
Roche
Amgen
Aveo Pharmaceuticals
Bayer
Exelixis
Eisai

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Surgery
Immunotherapy
Targeted Therapy
Other

Segment by Application

Renal Cell Carcinoma
Renal Pelvis Cancer
Other

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Kidney Cancer Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Kidney Cancer Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Kidney Cancer Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 Kidney Cancer Therapeutics Product Introduction

1.2 Global Kidney Cancer Therapeutics Market Size Forecast (2020-2031)

1.3 Kidney Cancer Therapeutics Market Trends & Drivers

1.3.1 Kidney Cancer Therapeutics Industry Trends

1.3.2 Kidney Cancer Therapeutics Market Drivers & Opportunity

1.3.3 Kidney Cancer Therapeutics Market Challenges

1.3.4 Kidney Cancer Therapeutics Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Kidney Cancer Therapeutics Players Revenue Ranking (2024)

2.2 Global Kidney Cancer Therapeutics Revenue by Company (2020-2025)

2.3 Key Companies Kidney Cancer Therapeutics Manufacturing Base Distribution and Headquarters

2.4 Key Companies Kidney Cancer Therapeutics Product Offered

2.5 Key Companies Time to Begin Mass Production of Kidney Cancer Therapeutics

2.6 Kidney Cancer Therapeutics Market Competitive Analysis

2.6.1 Kidney Cancer Therapeutics Market Concentration Rate (2020-2025)

2.6.2 Global 5 and 10 Largest Companies by Kidney Cancer Therapeutics Revenue in 2024

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Cancer Therapeutics as of 2024)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Surgery

3.1.2 Immunotherapy

3.1.3 Targeted Therapy

3.1.4 Other

3.2 Global Kidney Cancer Therapeutics Sales Value by Type

3.2.1 Global Kidney Cancer Therapeutics Sales Value by Type (2020 VS 2024 VS 2031)

3.2.2 Global Kidney Cancer Therapeutics Sales Value, by Type (2020-2031)

3.2.3 Global Kidney Cancer Therapeutics Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Renal Cell Carcinoma

4.1.2 Renal Pelvis Cancer

4.1.3 Other

4.2 Global Kidney Cancer Therapeutics Sales Value by Application

4.2.1 Global Kidney Cancer Therapeutics Sales Value by Application (2020 VS 2024 VS 2031)

4.2.2 Global Kidney Cancer Therapeutics Sales Value, by Application (2020-2031)

4.2.3 Global Kidney Cancer Therapeutics Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

5.1 Global Kidney Cancer Therapeutics Sales Value by Region

5.1.1 Global Kidney Cancer Therapeutics Sales Value by Region: 2020 VS 2024 VS 2031

5.1.2 Global Kidney Cancer Therapeutics Sales Value by Region (2020-2025)

5.1.3 Global Kidney Cancer Therapeutics Sales Value by Region (2026-2031)

5.1.4 Global Kidney Cancer Therapeutics Sales Value by Region (%), (2020-2031)

5.2 North America

5.2.1 North America Kidney Cancer Therapeutics Sales Value, 2020-2031

5.2.2 North America Kidney Cancer Therapeutics Sales Value by Country (%), 2024 VS 2031

5.3 Europe

5.3.1 Europe Kidney Cancer Therapeutics Sales Value, 2020-2031

5.3.2 Europe Kidney Cancer Therapeutics Sales Value by Country (%), 2024 VS 2031

5.4 Asia Pacific

5.4.1 Asia Pacific Kidney Cancer Therapeutics Sales Value, 2020-2031

5.4.2 Asia Pacific Kidney Cancer Therapeutics Sales Value by Region (%), 2024 VS 2031

5.5 South America

5.5.1 South America Kidney Cancer Therapeutics Sales Value, 2020-2031

5.5.2 South America Kidney Cancer Therapeutics Sales Value by Country (%), 2024 VS 2031

5.6 Middle East & Africa

5.6.1 Middle East & Africa Kidney Cancer Therapeutics Sales Value, 2020-2031

5.6.2 Middle East & Africa Kidney Cancer Therapeutics Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Kidney Cancer Therapeutics Sales Value Growth Trends, 2020 VS 2024 VS 2031

6.2 Key Countries/Regions Kidney Cancer Therapeutics Sales Value, 2020-2031

6.3 United States

6.3.1 United States Kidney Cancer Therapeutics Sales Value, 2020-2031

6.3.2 United States Kidney Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031

6.3.3 United States Kidney Cancer Therapeutics Sales Value by Application, 2024 VS 2031

6.4 Europe

6.4.1 Europe Kidney Cancer Therapeutics Sales Value, 2020-2031

6.4.2 Europe Kidney Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031

6.4.3 Europe Kidney Cancer Therapeutics Sales Value by Application, 2024 VS 2031

6.5 China

6.5.1 China Kidney Cancer Therapeutics Sales Value, 2020-2031

6.5.2 China Kidney Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031

6.5.3 China Kidney Cancer Therapeutics Sales Value by Application, 2024 VS 2031

6.6 Japan

6.6.1 Japan Kidney Cancer Therapeutics Sales Value, 2020-2031

6.6.2 Japan Kidney Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031

6.6.3 Japan Kidney Cancer Therapeutics Sales Value by Application, 2024 VS 2031

6.7 South Korea

6.7.1 South Korea Kidney Cancer Therapeutics Sales Value, 2020-2031

6.7.2 South Korea Kidney Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031

6.7.3 South Korea Kidney Cancer Therapeutics Sales Value by Application, 2024 VS 2031

6.8 Southeast Asia

6.8.1 Southeast Asia Kidney Cancer Therapeutics Sales Value, 2020-2031

6.8.2 Southeast Asia Kidney Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031

6.8.3 Southeast Asia Kidney Cancer Therapeutics Sales Value by Application, 2024 VS 2031

6.9 India

6.9.1 India Kidney Cancer Therapeutics Sales Value, 2020-2031

6.9.2 India Kidney Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031

6.9.3 India Kidney Cancer Therapeutics Sales Value by Application, 2024 VS 2031

7 Company Profiles

7.1 Merck

7.1.1 Merck Profile

7.1.2 Merck Main Business

7.1.3 Merck Kidney Cancer Therapeutics Products, Services and Solutions

7.1.4 Merck Kidney Cancer Therapeutics Revenue (US$ Million) & (2020-2025)

7.1.5 Merck Recent Developments

7.2 Novartis

7.2.1 Novartis Profile

7.2.2 Novartis Main Business

7.2.3 Novartis Kidney Cancer Therapeutics Products, Services and Solutions

7.2.4 Novartis Kidney Cancer Therapeutics Revenue (US$ Million) & (2020-2025)

7.2.5 Novartis Recent Developments

7.3 Bristol-Myers Squibb

7.3.1 Bristol-Myers Squibb Profile

7.3.2 Bristol-Myers Squibb Main Business

7.3.3 Bristol-Myers Squibb Kidney Cancer Therapeutics Products, Services and Solutions

7.3.4 Bristol-Myers Squibb Kidney Cancer Therapeutics Revenue (US$ Million) & (2020-2025)

7.3.5 Bristol-Myers Squibb Recent Developments

7.4 Pfizer

7.4.1 Pfizer Profile

7.4.2 Pfizer Main Business

7.4.3 Pfizer Kidney Cancer Therapeutics Products, Services and Solutions

7.4.4 Pfizer Kidney Cancer Therapeutics Revenue (US$ Million) & (2020-2025)

7.4.5 Pfizer Recent Developments

7.5 Roche

7.5.1 Roche Profile

7.5.2 Roche Main Business

7.5.3 Roche Kidney Cancer Therapeutics Products, Services and Solutions

7.5.4 Roche Kidney Cancer Therapeutics Revenue (US$ Million) & (2020-2025)

7.5.5 Roche Recent Developments

7.6 Amgen

7.6.1 Amgen Profile

7.6.2 Amgen Main Business

7.6.3 Amgen Kidney Cancer Therapeutics Products, Services and Solutions

7.6.4 Amgen Kidney Cancer Therapeutics Revenue (US$ Million) & (2020-2025)

7.6.5 Amgen Recent Developments

7.7 Aveo Pharmaceuticals

7.7.1 Aveo Pharmaceuticals Profile

7.7.2 Aveo Pharmaceuticals Main Business

7.7.3 Aveo Pharmaceuticals Kidney Cancer Therapeutics Products, Services and Solutions

7.7.4 Aveo Pharmaceuticals Kidney Cancer Therapeutics Revenue (US$ Million) & (2020-2025)

7.7.5 Aveo Pharmaceuticals Recent Developments

7.8 Bayer

7.8.1 Bayer Profile

7.8.2 Bayer Main Business

7.8.3 Bayer Kidney Cancer Therapeutics Products, Services and Solutions

7.8.4 Bayer Kidney Cancer Therapeutics Revenue (US$ Million) & (2020-2025)

7.8.5 Bayer Recent Developments

7.9 Exelixis

7.9.1 Exelixis Profile

7.9.2 Exelixis Main Business

7.9.3 Exelixis Kidney Cancer Therapeutics Products, Services and Solutions

7.9.4 Exelixis Kidney Cancer Therapeutics Revenue (US$ Million) & (2020-2025)

7.9.5 Exelixis Recent Developments

7.10 Eisai

7.10.1 Eisai Profile

7.10.2 Eisai Main Business

7.10.3 Eisai Kidney Cancer Therapeutics Products, Services and Solutions

7.10.4 Eisai Kidney Cancer Therapeutics Revenue (US$ Million) & (2020-2025)

7.10.5 Eisai Recent Developments

8 Industry Chain Analysis

8.1 Kidney Cancer Therapeutics Industrial Chain

8.2 Kidney Cancer Therapeutics Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Kidney Cancer Therapeutics Sales Model

8.5.2 Sales Channel

8.5.3 Kidney Cancer Therapeutics Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Kidney Cancer Therapeutics Market Trends

Table 2. Kidney Cancer Therapeutics Market Drivers & Opportunity

Table 3. Kidney Cancer Therapeutics Market Challenges

Table 4. Kidney Cancer Therapeutics Market Restraints

Table 5. Global Kidney Cancer Therapeutics Revenue by Company (2020-2025) & (US$ Million)

Table 6. Global Kidney Cancer Therapeutics Revenue Market Share by Company (2020-2025)

Table 7. Key Companies Kidney Cancer Therapeutics Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Kidney Cancer Therapeutics Product Type

Table 9. Key Companies Time to Begin Mass Production of Kidney Cancer Therapeutics

Table 10. Global Kidney Cancer Therapeutics Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Cancer Therapeutics as of 2024)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Kidney Cancer Therapeutics Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)

Table 14. Global Kidney Cancer Therapeutics Sales Value by Type (2020-2025) & (US$ Million)

Table 15. Global Kidney Cancer Therapeutics Sales Value by Type (2026-2031) & (US$ Million)

Table 16. Global Kidney Cancer Therapeutics Sales Market Share in Value by Type (2020-2025)

Table 17. Global Kidney Cancer Therapeutics Sales Market Share in Value by Type (2026-2031)

Table 18. Global Kidney Cancer Therapeutics Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)

Table 19. Global Kidney Cancer Therapeutics Sales Value by Application (2020-2025) & (US$ Million)

Table 20. Global Kidney Cancer Therapeutics Sales Value by Application (2026-2031) & (US$ Million)

Table 21. Global Kidney Cancer Therapeutics Sales Market Share in Value by Application (2020-2025)

Table 22. Global Kidney Cancer Therapeutics Sales Market Share in Value by Application (2026-2031)

Table 23. Global Kidney Cancer Therapeutics Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)

Table 24. Global Kidney Cancer Therapeutics Sales Value by Region (2020-2025) & (US$ Million)

Table 25. Global Kidney Cancer Therapeutics Sales Value by Region (2026-2031) & (US$ Million)

Table 26. Global Kidney Cancer Therapeutics Sales Value by Region (2020-2025) & (%)

Table 27. Global Kidney Cancer Therapeutics Sales Value by Region (2026-2031) & (%)

Table 28. Key Countries/Regions Kidney Cancer Therapeutics Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031

Table 29. Key Countries/Regions Kidney Cancer Therapeutics Sales Value, (2020-2025) & (US$ Million)

Table 30. Key Countries/Regions Kidney Cancer Therapeutics Sales Value, (2026-2031) & (US$ Million)

Table 31. Merck Basic Information List

Table 32. Merck Description and Business Overview

Table 33. Merck Kidney Cancer Therapeutics Products, Services and Solutions

Table 34. Revenue (US$ Million) in Kidney Cancer Therapeutics Business of Merck (2020-2025)

Table 35. Merck Recent Developments

Table 36. Novartis Basic Information List

Table 37. Novartis Description and Business Overview

Table 38. Novartis Kidney Cancer Therapeutics Products, Services and Solutions

Table 39. Revenue (US$ Million) in Kidney Cancer Therapeutics Business of Novartis (2020-2025)

Table 40. Novartis Recent Developments

Table 41. Bristol-Myers Squibb Basic Information List

Table 42. Bristol-Myers Squibb Description and Business Overview

Table 43. Bristol-Myers Squibb Kidney Cancer Therapeutics Products, Services and Solutions

Table 44. Revenue (US$ Million) in Kidney Cancer Therapeutics Business of Bristol-Myers Squibb (2020-2025)

Table 45. Bristol-Myers Squibb Recent Developments

Table 46. Pfizer Basic Information List

Table 47. Pfizer Description and Business Overview

Table 48. Pfizer Kidney Cancer Therapeutics Products, Services and Solutions

Table 49. Revenue (US$ Million) in Kidney Cancer Therapeutics Business of Pfizer (2020-2025)

Table 50. Pfizer Recent Developments

Table 51. Roche Basic Information List

Table 52. Roche Description and Business Overview

Table 53. Roche Kidney Cancer Therapeutics Products, Services and Solutions

Table 54. Revenue (US$ Million) in Kidney Cancer Therapeutics Business of Roche (2020-2025)

Table 55. Roche Recent Developments

Table 56. Amgen Basic Information List

Table 57. Amgen Description and Business Overview

Table 58. Amgen Kidney Cancer Therapeutics Products, Services and Solutions

Table 59. Revenue (US$ Million) in Kidney Cancer Therapeutics Business of Amgen (2020-2025)

Table 60. Amgen Recent Developments

Table 61. Aveo Pharmaceuticals Basic Information List

Table 62. Aveo Pharmaceuticals Description and Business Overview

Table 63. Aveo Pharmaceuticals Kidney Cancer Therapeutics Products, Services and Solutions

Table 64. Revenue (US$ Million) in Kidney Cancer Therapeutics Business of Aveo Pharmaceuticals (2020-2025)

Table 65. Aveo Pharmaceuticals Recent Developments

Table 66. Bayer Basic Information List

Table 67. Bayer Description and Business Overview

Table 68. Bayer Kidney Cancer Therapeutics Products, Services and Solutions

Table 69. Revenue (US$ Million) in Kidney Cancer Therapeutics Business of Bayer (2020-2025)

Table 70. Bayer Recent Developments

Table 71. Exelixis Basic Information List

Table 72. Exelixis Description and Business Overview

Table 73. Exelixis Kidney Cancer Therapeutics Products, Services and Solutions

Table 74. Revenue (US$ Million) in Kidney Cancer Therapeutics Business of Exelixis (2020-2025)

Table 75. Exelixis Recent Developments

Table 76. Eisai Basic Information List

Table 77. Eisai Description and Business Overview

Table 78. Eisai Kidney Cancer Therapeutics Products, Services and Solutions

Table 79. Revenue (US$ Million) in Kidney Cancer Therapeutics Business of Eisai (2020-2025)

Table 80. Eisai Recent Developments

Table 81. Key Raw Materials Lists

Table 82. Raw Materials Key Suppliers Lists

Table 83. Kidney Cancer Therapeutics Downstream Customers

Table 84. Kidney Cancer Therapeutics Distributors List

Table 85. Research Programs/Design for This Report

Table 86. Key Data Information from Secondary Sources

Table 87. Key Data Information from Primary Sources

Table 88. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Kidney Cancer Therapeutics Product Picture

Figure 2. Global Kidney Cancer Therapeutics Sales Value, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Global Kidney Cancer Therapeutics Sales Value (2020-2031) & (US$ Million)

Figure 4. Kidney Cancer Therapeutics Report Years Considered

Figure 5. Global Kidney Cancer Therapeutics Players Revenue Ranking (2024) & (US$ Million)

Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Kidney Cancer Therapeutics Revenue in 2024

Figure 7. Kidney Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 8. Surgery Picture

Figure 9. Immunotherapy Picture

Figure 10. Targeted Therapy Picture

Figure 11. Other Picture

Figure 12. Global Kidney Cancer Therapeutics Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)

Figure 13. Global Kidney Cancer Therapeutics Sales Value Market Share by Type, 2024 & 2031

Figure 14. Product Picture of Renal Cell Carcinoma

Figure 15. Product Picture of Renal Pelvis Cancer

Figure 16. Product Picture of Other

Figure 17. Global Kidney Cancer Therapeutics Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)

Figure 18. Global Kidney Cancer Therapeutics Sales Value Market Share by Application, 2024 & 2031

Figure 19. North America Kidney Cancer Therapeutics Sales Value (2020-2031) & (US$ Million)

Figure 20. North America Kidney Cancer Therapeutics Sales Value by Country (%), 2024 VS 2031

Figure 21. Europe Kidney Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 22. Europe Kidney Cancer Therapeutics Sales Value by Country (%), 2024 VS 2031

Figure 23. Asia Pacific Kidney Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 24. Asia Pacific Kidney Cancer Therapeutics Sales Value by Region (%), 2024 VS 2031

Figure 25. South America Kidney Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 26. South America Kidney Cancer Therapeutics Sales Value by Country (%), 2024 VS 2031

Figure 27. Middle East & Africa Kidney Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 28. Middle East & Africa Kidney Cancer Therapeutics Sales Value by Country (%), 2024 VS 2031

Figure 29. Key Countries/Regions Kidney Cancer Therapeutics Sales Value (%), (2020-2031)

Figure 30. United States Kidney Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 31. United States Kidney Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031

Figure 32. United States Kidney Cancer Therapeutics Sales Value by Application (%), 2024 VS 2031

Figure 33. Europe Kidney Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 34. Europe Kidney Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031

Figure 35. Europe Kidney Cancer Therapeutics Sales Value by Application (%), 2024 VS 2031

Figure 36. China Kidney Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 37. China Kidney Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031

Figure 38. China Kidney Cancer Therapeutics Sales Value by Application (%), 2024 VS 2031

Figure 39. Japan Kidney Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 40. Japan Kidney Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031

Figure 41. Japan Kidney Cancer Therapeutics Sales Value by Application (%), 2024 VS 2031

Figure 42. South Korea Kidney Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 43. South Korea Kidney Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031

Figure 44. South Korea Kidney Cancer Therapeutics Sales Value by Application (%), 2024 VS 2031

Figure 45. Southeast Asia Kidney Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 46. Southeast Asia Kidney Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031

Figure 47. Southeast Asia Kidney Cancer Therapeutics Sales Value by Application (%), 2024 VS 2031

Figure 48. India Kidney Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 49. India Kidney Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031

Figure 50. India Kidney Cancer Therapeutics Sales Value by Application (%), 2024 VS 2031

Figure 51. Kidney Cancer Therapeutics Industrial Chain

Figure 52. Kidney Cancer Therapeutics Manufacturing Cost Structure

Figure 53. Channels of Distribution (Direct Sales, and Distribution)

Figure 54. Bottom-up and Top-down Approaches for This Report

Figure 55. Data Triangulation

Figure 56. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which region is expected to have the highest market share? zhanKai

For each regional market, the report conducted in-depth comparative analysis from multiple dimensions such as market size, 3.8% compound annual growth rate, market demand, industrial structure, policy environment, and the layout of major enterprises. It systematically summarized the market characteristics and competitive environment of different regions. At the same time, it also focused on analyzing the demand structure, market growth drivers, and investment environment of each region, providing valuable references for enterprises to identify key regional markets, formulate global market layouts and sales strategies.

Which companies rank high in the global Kidney Cancer Therapeutics market? shouQi

What was the global market size of Kidney Cancer Therapeutics in 2031? shouQi

What is the annual compound growth rate of the global Kidney Cancer Therapeutics market size from 2025 to 2031? shouQi

What was the global market size of Kidney Cancer Therapeutics in 2025? shouQi

Related Reports

Global Kidney Cancer Therapeutics Market Research Report 2025
The global market for Kidney Cancer Therapeutics was valued at US$ 452 million in the year 2024 and is projected to reach a revised size of US$ 585 million by 2031, growing at a CAGR of 3.8% during the forecast period.
Published Date: 2025-01-13
Pages: 78
USD 2900.00
(Single User License)
Global Kidney Cancer Therapeutics Market Insights, Forecast to 2030
Kidney cancer is cancer that begins in the kidneys. Your kidneys are two bean-shaped organs, each about the size of your fist. They're located behind your abdominal organs, with one kidney on each side of your spine. In adults, renal cell carcinoma is the most common type of kidney cancer.
Published Date: 2024-04-15
Pages: 111
USD 4900.00
(Single User License)
Global Kidney Cancer Therapeutics Market Research Report 2024
Kidney cancer is cancer that begins in the kidneys. Your kidneys are two bean-shaped organs, each about the size of your fist. They're located behind your abdominal organs, with one kidney on each side of your spine. In adults, renal cell carcinoma is the most common type of kidney cancer.
Published Date: 2024-01-17
Pages: 87
USD 2900.00
(Single User License)

Global Kidney Cancer Therapeutics Market Research Report 2025
The global market for Kidney Cancer Therapeutics was valued at US$ 452 million in the year 2024 and is projected to reach a revised size of US$ 585 million by 2031, growing at a CAGR of 3.8% during the forecast period.
Published: 2025-01-13
Pages: 78
USD 2900.00 (Single User License)
Global Kidney Cancer Therapeutics Market Insights, Forecast to 2030
Kidney cancer is cancer that begins in the kidneys. Your kidneys are two bean-shaped organs, each about the size of your fist. They're located behind your abdominal organs, with one kidney on each side of your spine. In adults, renal cell carcinoma is the most common type of kidney cancer.
Published: 2024-04-15
Pages: 111
USD 4900.00 (Single User License)
Global Kidney Cancer Therapeutics Market Research Report 2024
Kidney cancer is cancer that begins in the kidneys. Your kidneys are two bean-shaped organs, each about the size of your fist. They're located behind your abdominal organs, with one kidney on each side of your spine. In adults, renal cell carcinoma is the most common type of kidney cancer.
Published: 2024-01-17
Pages: 87
USD 2900.00 (Single User License)